Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials
Therapy-related side effects and severe antimicrobial resistance still remain an obstacle to Helicobacter pylori eradication. This meta-analysis aimed to investigate the efficacy of Lactobacillus-supplemented triple therapy on H. pylori eradication rates and therapy-related side effects in children. Five studies involving 484 pediatric patients were included in our analysis. The pooled relative risk (RR) for eradication rates in the Lactobacillus group versus the control group was 1.19 [95% confidence interval (CI) 1.07–1.33]. In subgroup analyses based on dose and duration of Lactobacillus supplementation, the pooled RRs for eradication rates were 1.36 (95% CI 1.15–1.60) in the high-dose group, 1.08 (95% CI 0.86–1.35) in the low-dose group, 1.24 (95% CI 1.06–1.46) in the long-term group, and 1.17 (95% CI 0.96–1.44) in the short-term group. With respect to side effects, Lactobacillus supplementation significantly reduced the incidence of diarrhea (RR = 0.30, 95% CI 0.10–0.85).
What is Known:
• Probiotics-supplemented triple therapy may be beneficial in improving H. pylori eradication rates and reducing therapy-related side effects in children. However, not all probiotics are beneficial to H. pylori eradication and the pooled outcomes based on different probiotics may be erroneously extrapolated to other ineffective strains.
What is New:
• Lactobacillus, as an adjunct to triple therapy, can increase H. pylori eradication rates as well as reduce the incidence of therapy-related diarrhea in children.
KeywordsLactobacillus Triple therapy H. pylori Children Meta-analysis
H. pylori stool antigen test
Nonsteroidal anti-inflammatory drug
Randomized controlled trial
Rapid urease test
Proton pump inhibitor
Urea breath test
H-RF: study design, search and selection of articles, data extraction, statistical analysis, drafting the manuscript; G-QZ: data extraction, quality assessment, statistical analysis, revising the manuscript; J-YC: search and selection of articles, quality assessment, statistical analysis; Z-YL: study design, statistical analysis, drafting, and revising the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Not applicable for this manuscript.
Not applicable for this manuscript.
- 1.Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M, ESPGHAN, NASPGHAN (2017) Joint ESPGHAN/NASPGHAN guidelines for the Management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr 64:991–1003. https://doi.org/10.1097/MPG.0000000000001594 CrossRefGoogle Scholar
- 7.Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW, Harrison G, Trowell JE (1992) Experience with ‘triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 6:427–435CrossRefGoogle Scholar
- 8.Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP, the European Registry on H. pylori management (Hp-EuReg) (2015) Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Alimet Pharmacol Ther 41:581–589. https://doi.org/10.1111/apt.13069 CrossRefGoogle Scholar
- 9.Joint FAO/WHO Working Group (2002) Report on drafting guidelines for the evaluation of probiotics in food. Available at: www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed 7 July 2018
- 10.Li S, Huang XL, Sui JZ, Chen SY, Xie YT, Deng Y, Wang J, Xie L, Li TJ, He Y, Peng QL, Qin X, Zeng ZY (2014) Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr 173:153–161. https://doi.org/10.1007/s00431-013-2220-3 CrossRefGoogle Scholar
- 14.Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, de Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL (2008) Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13:127–134. https://doi.org/10.1111/j.1523-5378.2008.00593.x CrossRefGoogle Scholar
- 15.Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A (2004) In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 70:518–526. https://doi.org/10.1128/AEM.70.1.518-526.2004 CrossRefGoogle Scholar
- 22.Bernet-Camard MF, Lievin V, Brassart D, Neeser JR, Servin AL, Hudault S (1997) The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Appl Environ Microbiol 63:2747–2753Google Scholar
- 24.Bhatia SJ, Kochar N, Abraham P, Nair NG, Metha AP (1989) Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 27:2328–2330Google Scholar
- 25.Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, Felley C, Porta N, Rouvet M, Blum AL, Corthésy-Theulaz I (1999) Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60:203–209. https://doi.org/10.1159/000007660 CrossRefGoogle Scholar
- 26.Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available at: www.handbook-5-1.cochrane.org/. Accessed 13 June 2018
- 27.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–34. https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRefGoogle Scholar
- 28.Schunemann H, Brozek J, Guyatt G et al (2013) GRADE handbook for grading quality of evidence and strength of recommendations (Updated October 2013). The GRADE Working Group Available at: www.guidelinedevelopment.org/handbook
- 29.Zhu XL, Liu Z, Wu ZQ, Li D, Jiang AP, Yu GX (2017) Clinical effects of different therapeutic regimens for Helicobacter pylori infection in children. Zhong Guo Dang Dai Er Ke Za Zhi 19:672–676. https://doi.org/10.7499/j.issn.1008-8830.2017.06.012 Google Scholar
- 32.Szajewska H, Albrecht P, Topczewska-Cabanek A (2009) Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr 48:431–436. https://doi.org/10.1097/MPG.0b013e318182e716 CrossRefGoogle Scholar
- 33.Sykora J, Valeckova K, Amlerova J, Siala K, Dedek P, Watkins S, Varvarovska J, Stozicky F, Pazdiora P, Schwarz J (2005) Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol 39:692–698CrossRefGoogle Scholar
- 34.Shahraki T, Shahraki M, Shahri ES, Mohammadi M (2017) No significant impact of Lactobacillus reuteri on eradication of Helicobacter pylori in children (double-blind randomized clinical trial). Iran Red Crescent Med J 19:e42101Google Scholar
- 35.Saneeyan H, Layegh S, Rahimi H (2011) Effectiveness of probiotic on treatment of Helicobacter pylori infection in children. J Isfahan Med Sch 29:882–889Google Scholar
- 36.Plewinska EM, Planeta-Malecka I, Bak-Romaniszyn L, Czkwianlanc E, Malecka-Panas E (2006) Probiotics in the treatment of Helicobacter pylori infection in children. Gastroenterol Pol 13(315–3):19Google Scholar
- 37.Ahmad K, Fatemeh F, Mehri N, Maryam S (2013) Probiotics for the treatment of pediatric Helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr 23:79–84Google Scholar
- 40.Wang ZH, Gao QY, Fang JY (2013) Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 47:25–32. https://doi.org/10.1097/MCG.0b013e318266f6cf CrossRefGoogle Scholar
- 42.Feng JR, Wang F, Qiu X, McFarland LV, Chen PF, Zhou R, Liu J, Zhao Q, Li J (2017) Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol 73:1199–1208. https://doi.org/10.1007/s00228-017-2291-6 CrossRefGoogle Scholar